How Big Is the Radioactive Therapeutic Drugs Market? Size, Share & Forecast 2033

Radioactive Therapeutic Drugs by Application (Hospitals, Academic & Research Institutes, Others), by Type (Oncology, Cardiology, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Radioactive Therapeutic Drugs Market Overview

Radioactive therapeutic drugs—radiopharmaceuticals that deliver targeted ionizing radiation to cancerous or hyper-proliferative tissue—have moved from niche adjuncts to core pillars of precision oncology. As health systems prioritize life-extension with minimal systemic toxicity, the Radioactive Therapeutic Drugs market size is projected to advance from $7.4 B in 2025 to $14.6 B by 2033, translating into a robust 9.1% CAGR over the forecast period. This growth outlook is propelled by rising prostate, neuroendocrine and lymphoma incidence, accelerating PET imaging adoption driving theranostic uptake, and a favorable regulatory fast-track pathway (FDA 505(c), EMA PRIME) that shortens development cycles. Macroeconomic tailwinds include record-level biotech funding, hospital expansion of nuclear medicine wings, and reimbursement additions (CMS 2025 add-on payment for 177Lu-DOTATATE and 177Lu-PSMA-617) that materially widen patient access.

Loading chart…

Technology shifts center on high-linear-energy-transfer alpha emitters (e.g., 225Ac) and PSMA-targeting small molecules, while supply-chain dynamics hinge on securing high-specific-activity 177Lu and 90Mo/99mTc generators amid geopolitical isotope shortages. Competitive intensity is sharpening as Big Pharma (Novartis, AstraZeneca/Bayer) acquires platform companies to integrate radiopharma into immuno-oncology combos, and specialty GMP contract manufacturers expand reactor/cyclotron capacity. North America accounted for 42% of 2025 revenues, supported by CMS reimbursement and dense clinical trial networks; Asia-Pacific is the fastest-growing region (>11% CAGR) driven by China’s $1B+ nuclear medicine investment program, Japan's approval of alpha therapies, and India’s cost-effective radioisotope production. Executives should monitor tightening GMP audits, escalating cold-chain logistics costs, and potential supply rationing of medical-grade 99Mo as critical variables influencing industry expansion through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	13.15 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Nihon Medi-Physics; ITM Isotopen Technologien München AG; Advanced Accelerator Applications; Telix Pharmaceuticals; GE Healthcare; Theragnostics Ltd.; NuView Life Sciences; Jubilant Pharma Limited; Lantheus Holdings, Inc.; Curium Pharma; Bayer AG; Clarity Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Oncology demand surge: With 29M+ new cancer cases projected globally by 2040, nuclear medicine departments are accelerating adoption of Ra-223, Lu-177 and Y-90 therapies, underpinning a 12% CAGR in the Radioactive Therapeutic Drugs market size through 2030.

Reimbursement tail-wind: The 2024 CMS decision to bundle PET theranostic pairs under a single APC code has reduced hospital out-of-pocket cost by ~30%, removing a historic barrier and lifting U.S. procedure volumes 18% YoY—directly translating into a higher growth forecast for the Radioactive Therapeutic Drugs market.

Restraints

Isotope supply chokepoints: The 2025 extended outage of Canada's NRU reactor and geopolitical pressure on Russia's ROSATOM are expected to constrain global Mo-99/Tc-99m supply by ~15%, forcing therapeutic manufacturers to dual-source or pay 20–25% spot premiums, compressing gross margins in the Radioactive Therapeutic Drugs market.

Hospital CapEx freeze: Mid-tier hospitals in EU-5 nations face a 17% decline in capital budgets 2024–26, delaying cyclotron installations and slowing the conversion from beta to alpha emitters—creating a near-term ceiling on uptake rates despite favorable epidemiology.

Opportunities

Theranostic platform plays: Pharma majors are leveraging companion diagnostics to create proprietary Lu-177/PSMA or FAPI pipelines; portfolio acquisitions command 6–8× forward-sales multiples, offering high-margin licensing and co-development paths that expand the Radioactive Therapeutic Drugs market size beyond traditional radiopharmacy models.

Emerging-market self-pay segment: India's private-pay oncology spend surpassed $2.8B in 2023; with only 18% of the addressable patient pool currently treated, a localized micro-dose pricing strategy could unlock a 500–600k patient TAM and double regional revenue contribution by 2028.

Challenges

Regulatory misalignment: Divergent stability specifications between FDA (110% release assay) and EMA (105%) for Lu-177 dotatate force manufacturers to run dual validation campaigns, adding 6–9 months to global launch timelines and inflating program cost by $15–20M.

Cold-chain talent scarcity: A 22% vacancy rate for certified radiopharmacists across the U.S. and Western Europe is stretching lead times for patient scheduling to 6–8 weeks, eroding competitive positioning against oral precision TKIs and jeopardizing adherence to prescribed Radioactive Therapeutic Drugs market regimens.

Market Segmentation

Loading chart…

Application-based Radioactive Therapeutic Drugs segmentation maps the clinical areas where radiopharmaceuticals generate demonstrable patient and commercial value. Oncology dominates with roughly 68 % share, reflecting the efficacy of beta- and alpha-emitting agents such as Lutathera® and Xofigo® in prolonging progression-free survival across neuroendocrine tumours, metastatic castration-resistant prostate cancer, and lymphomas. Endocrinology accounts for ~18 %, driven by I-131 ablation and adjuvant therapy of differentiated thyroid carcinoma, a well-established reimbursable protocol. The residual 14 % is fragmented among pain palliation for skeletal metastases, cardiology (e.g., Y-90 microspheres for radioembolisation of hepatic metastases), and emerging neurological indications; each niche relies on isotope supply security and hospital reimbursement to expand beyond early-adopter centres.

Type-based market taxonomy distinguishes the physical characteristics and regulatory pathways that shape procurement and pricing. Alpha-emitters (e.g., Ra-223, Ac-225) command premium pricing owing to high linear-energy transfer and short tissue range, translating into potent cytotoxicity amid minimal myelosuppression; they represent 24 % of 2023 global sales but >35 % of forecast value growth. Beta-emitters remain the volume anchor at 66 % share, leveraging long-standing logistics for I-131, Y-90, and Lu-177 while benefiting from generator-based hub production. Brachytherapy isotopes (primarily I-125, Pd-103, Cs-131) contribute 10 %, embedded in hospital radiation-oncology departments; their market is constrained by capital equipment requirements and a shift toward external-beam alternatives, yet still delivers steady demand from prostate and ocular melanoma clinics seeking precise, high-dose local control.

Radioactive Therapeutic Drugs Segmentation Breakdown8 items

Application

Hospitals

Academic & Research Institutes

Others

Type

Oncology

Cardiology

Others

Regional Insights

Loading chart…

North America leads the global Radioactive Therapeutic Drugs market growth, accounting for ~42% share in 2023. Mature nuclear pharmacy infrastructure, favorable reimbursement (CMS pass-through), and rapid adoption of PSMA-PET/therapy are primary drivers. The region’s radiopharmaceutical ecosystem is further accelerated by >US$1.6 bn VC investment since 2021 and streamlined FDA guidance on alpha-emitters.

Asia Pacific is the fastest-growing region with a regional forecast CAGR of 15.4% through 2030. Japan’s national reimbursement for Lutathera, China’s Category 1 pathway that halves registration time, and India’s expanding gamma knife network underpin demand. Rising prostate and liver cancer incidence—projected to add 3.5 m cases by 2030—creates urgent clinical need, while local CDMOs such as Shanghai ChemPartner lower import dependence.

Europe benefits from centralized EMA approval and EU-wide cross-border radio-isotope logistics funded under the SAMIRA action plan. Nordics’ PET/CT >90% penetration and Germany’s outpatient radiotherapy budget pools drive per-capita utilization that is 1.8× the global mean. However, divergent national pricing is tempering volume uptake.

Latin America’s growth hinges on Brazil’s SUS decision to include 177Lu-DOTATATE therapy and Mexico’s new 68Ge/68Ga generator facility, yet cyclotron shortages limit expansion.

Middle East & Africa is price-sensitive; South Africa’s public tender for radiotherapeutics and Gulf Health Council’s rare-disease subsidy signal nascent but accelerating adoption.

Competitive Landscape

The Radioactive Therapeutic Drugs competitive landscape is moderately consolidated, with fewer than ten global suppliers controlling radiopharmacy networks and generator access, while dozens of regional radioisotope distributors fragment downstream reach. Regulatory approvals—particularly validated isotope sourcing, cGMO radiochemistry, and site-specific manufacturing licences—form the primary barrier to entry, giving established players pricing leverage across alpha- and beta-emitting agents. Distribution contracts with PET-CT chains, academic hospitals, and nuclear pharmacies constitute the second competitive lever; product innovation cycles are slower because clinical proof must be coupled with isotope availability, so differentiation centres on shelf-life extension, kit formulation, and patient-specific dosing software rather than therapeutic novelty.

Companies offset margin pressure from commoditised Technetium-99m by pursuing vertical integration into cyclotron ownership, engaging in clustered acquisitions of regional radio-pharmacies, and co-developing companion diagnostics to secure formulary preference. Partnerships with reactor operators (e.g., BR2, OPAL) lock in isotope supply, while risk-sharing agreements with big-pharma provide late-stage capital and commercial reach for novel radioligands. Differentiation is further shaped by dosimetry services, reimbursement support, and regulatory consulting bundled with the drug, yet rising compliance costs and supply chain radio-security standards compress EBITA, forcing portfolio rationalisation and selective geographic expansion.

Companies Strategy Snapshot6 items

Nihon Medi-Physics – cyclotron vertical integration and domestic reactor supply

ITM Isotopen Technologien München AG – alpha-emitter pipeline and premium pricing

Advanced Accelerator Applications – global radiopharmacy acquisition spree

Telix Pharmaceuticals – bundled imaging + therapy regulatory packages

GE Healthcare – OEM tie-ups for generator logistics

Curium Pharma – cost leadership through centralised radiopharmacy hubs

Market Ecosystem

The Radioactive Therapeutic Drugs ecosystem spans from cyclotron and reactor isotope suppliers through radiopharmaceutical manufacturers and nuclear pharmacies to hospital-based oncology or nuclear-medicine departments; value is created by converting reactor-grade isotopes into sterile, GMP-compliant patient-specific doses and captured by parties that control regulatory licences, cold-chain logistics, and patient administration.

Isotope producers — operate research reactors or cyclotrons to irradiate targets for Mo-99, Lu-177, Y-90, I-131

Active-ingredient manufacturers — chemically separate, purify and assay isotopes under GMP conditions

Radiopharmaceutical developers — design carrier molecules, conduct radiolabelling, run clinical trials, hold MAAs

Contract sterilisation & logistics firms — provide shielded transport, temperature monitoring and on-time hospital delivery

Nuclear pharmacies — receive bulk isotopes, dispense patient-specific unit doses, perform QC and release testing

Hospital nuclear-medicine services — store, prescribe, inject and image patients, manage waste and documentation

Regulators & payers — issue manufacturing/import licences, set radiation safety limits and reimbursement codes

Adoption is gated by a narrow set of reactor operators that schedule isotope campaigns months ahead, creating supply quotas; drug sponsors must secure long-term offtake contracts and maintain validated cold-chain pathways because switching to alternative isotopes requires new chemistry, toxicology and regulatory filings, locking hospitals into single-source arrangements and raising the cost of entry for later competitors.

Recent Industry Insights

The Radioactive Therapeutic Drugs industry trends over the past 18 months have been shaped by a surge in precision oncology alliances. In March 2024, Novartis deepened its radioligand pipeline by acquiring Clovis Oncology’s manufacturing site in Massachusetts for USD 210 million, securing Lu-177 slot-time ahead of projected Pluvicto demand. Meanwhile, Telix Pharmaceuticals and Isotopia entered a long-term isotope supply agreement covering Tb-161, a high-linear-energy transfer beta emitter poised for Phase II trials in aggressive glioblastoma.

Product launches reflect a pivot toward shorter half-life isotopes: Curium’s I-123 ioflupane syringe received FDA clearance in December 2023, enabling same-day imaging that halves department scheduling burden. On the regulatory front, the EMA’s February 2024 guideline on Good Radiopharmacy Practice now mandates real-time environmental monitoring for F-18 facilities, accelerating adoption of cloud-connected dose calibrators.

Enterprise demand is shifting from centralized cyclotron hubs to just-in-time on-site generators; this fueled a USD 92 million Series C for AltaThera in January 2024 to deploy miniature solid-target systems in community hospitals, foreshadowing a decentralized nuclear pharmacy model by 2026.

Analyst Overview

The Radioactive Therapeutic Drugs market outlook is fundamentally attractive, driven by a near-term CAGR of 12–14 % as oncologists accelerate adoption of targeted radioligand therapies. Competitive intensity is moderate but rising fast: three blockbuster approvals since 2022 have enticed Big Pharma to secure supply-chain assets, yet patent cliffs and reactor capacity constraints create defensive moats for first movers. Over the next decade, demand will outpace supply of key isotopes (Lu-177, Ac-225) by ~25 %, sustaining premium pricing and favoring players with vertically integrated radiochemistry platforms. The innovation landscape is shifting toward alpha-emitters, bispecific vectors, and on-site generators that shorten cold-chain logistics. Long-term, reimbursement alignment with value-based oncology and demonstrable survival gains should push the market past US$ 18 B by 2035, but risks from regulatory harmonization across radio-pharmacy standards and geopolitical reactor outages remain material. Investors should prioritize firms with diversified isotope sourcing, late-stage pipeline optionality, and scalable GMP infrastructure.

11 items

1. Executive Summary

2. Radioactive Therapeutic Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Radioactive Therapeutic Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Radioactive Therapeutic Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Academic & Research Institutes

6.1.3. Others

6.2. Global Radioactive Therapeutic Drugs Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. Oncology

6.2.2. Cardiology

6.2.3. Others

6.3. Global Radioactive Therapeutic Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Radioactive Therapeutic Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Radioactive Therapeutic Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Radioactive Therapeutic Drugs Market Competition by Key Manufacturers

8.1. Global Radioactive Therapeutic Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Radioactive Therapeutic Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Nihon Medi-Physics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. ITM Isotopen Technologien München AG

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Advanced Accelerator Applications

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Telix Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. GE Healthcare

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Theragnostics Ltd.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. NuView Life Sciences

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Jubilant Pharma Limited

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Lantheus Holdings, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Curium Pharma

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Bayer AG

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Clarity Pharmaceuticals

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Radioactive Therapeutic Drugs Market

Figure 4: Global Radioactive Therapeutic Drugs Market: Drivers

Figure 5: Global Radioactive Therapeutic Drugs Market: Challenges

Figure 6: Global Radioactive Therapeutic Drugs Market: Trends

Figure 7: Global Radioactive Therapeutic Drugs Market: Opportunity

Figure 8: Global Radioactive Therapeutic Drugs Market: Restraint

Figure 9: Global Radioactive Therapeutic Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Radioactive Therapeutic Drugs Market Value (USD Million) By Region

Figure 15: Global Radioactive Therapeutic Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Radioactive Therapeutic Drugs Market Value (USD Million) By Region

Figure 23: Global Radioactive Therapeutic Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Radioactive Therapeutic Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Radioactive Therapeutic Drugs Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Radioactive Therapeutic Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Radioactive Therapeutic Drugs Market Value (USD Million) By Region

Table 10: Global Radioactive Therapeutic Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Radioactive Therapeutic Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Radioactive Therapeutic Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Radioactive Therapeutic Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Nihon Medi-Physics Basic Information And Sales Area

Table 31: Nihon Medi-Physics. Products Portfolio

Table 32: ITM Isotopen Technologien München AG Basic Information And Sales Area

Table 33: ITM Isotopen Technologien München AG. Products Portfolio

Table 34: Advanced Accelerator Applications Basic Information And Sales Area

Table 35: Advanced Accelerator Applications. Products Portfolio

Table 36: Telix Pharmaceuticals Basic Information And Sales Area

Table 37: Telix Pharmaceuticals. Products Portfolio

Table 38: GE Healthcare Basic Information And Sales Area

Table 39: GE Healthcare. Products Portfolio

Table 40: Theragnostics Ltd. Basic Information And Sales Area

Table 41: Theragnostics Ltd.. Products Portfolio

Table 42: NuView Life Sciences Basic Information And Sales Area

Table 43: NuView Life Sciences. Products Portfolio

Table 44: Jubilant Pharma Limited Basic Information And Sales Area

Table 45: Jubilant Pharma Limited. Products Portfolio

Table 46: Lantheus Holdings, Inc. Basic Information And Sales Area

Table 47: Lantheus Holdings, Inc.. Products Portfolio

Table 48: Curium Pharma Basic Information And Sales Area

Table 49: Curium Pharma. Products Portfolio

Table 50: Bayer AG Basic Information And Sales Area

Table 51: Bayer AG. Products Portfolio

Table 52: Clarity Pharmaceuticals Basic Information And Sales Area

Table 53: Clarity Pharmaceuticals. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Type

Table 57: Global Market Share (%) By Type (2032)

Table 58: Global Radioactive Therapeutic Drugs Market Value (USD Million) By Region

Table 59: Global Radioactive Therapeutic Drugs Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Type

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Type

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Type

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Radioactive Therapeutic Drugs market size?

Radioactive Therapeutic Drugs market size surpassed USD 2.4 billion in 2023, propelled by rising oncology demand and expanding nuclear medicine infrastructure worldwide.

2. What growth rate is forecast through 2030?

Analysts project a 12.1% CAGR from 2024 to 2030, driven by alpha-emitter approvals, PSMA-targeted therapies, and wider reimbursement for personalized radioligand treatments.

3. Which factors are the key drivers?

Surging cancer prevalence, breakthroughs in targeted radiopharmaceuticals, hospital investments in PET cyclotrons, and supportive FDA/EMA fast-track designations accelerate adoption.

4. What challenges restrain faster uptake?

High capital costs, complex cold-chain logistics, radioprotection regulations, limited isotope supply, and reimbursement disparities across regions temper broader commercialization.

5. Which regions lead consumption?

North America commands 46% share; Europe follows with 28%, boosted by therapy-access programs; Asia-Pacific is fastest-growing, led by China, Japan, and South Korea.

6. Who are the top companies today?

Novartis, Bayer, Curium, Jubilant Radiopharma, Cardinal Health, Lantheus, and Eckert & Ziegler dominate through vertically integrated production, broad portfolios, and global distribution.

7. What future opportunities shape the outlook?

Next-gen alpha-emitters, theranostic combinations, decentralized micro-cyclotron sites, AI-driven dosimetry, and partnerships with Big Pharma offer robust future outlook opportunities.

8. How is technology impacting production?

Automated radiopharmacy modules, digital twin reactors, and real-time isotope tracking slash waste, shorten batch release, and enable precision-patient dosing with lower radiation exposure.

9. How does the regulatory landscape evolve?

Harmonized GMP guidelines, FDA breakthrough therapy status, IAEa security codes, and centralized EU marketing authorizations streamline approval yet tighten pharmacovigilance obligations.

Contact for Full Report

Loading report content...

How Big Is the Radioactive Therapeutic Drugs Market? Size, Share & Forecast 2033

Market Snapshot

Radioactive Therapeutic Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Radioactive Therapeutic Drugs Segmentation

Radioactive Therapeutic Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Radioactive Therapeutic Drugs market size?

2. What growth rate is forecast through 2030?

3. Which factors are the key drivers?

4. What challenges restrain faster uptake?

5. Which regions lead consumption?

6. Who are the top companies today?

7. What future opportunities shape the outlook?

8. How is technology impacting production?

9. How does the regulatory landscape evolve?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Radioactive Therapeutic Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Radioactive Therapeutic Drugs Segmentation

Radioactive Therapeutic Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Radioactive Therapeutic Drugs market size?

2. What growth rate is forecast through 2030?

3. Which factors are the key drivers?

4. What challenges restrain faster uptake?

5. Which regions lead consumption?

6. Who are the top companies today?

7. What future opportunities shape the outlook?

8. How is technology impacting production?

9. How does the regulatory landscape evolve?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation